Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. GINA definition of asthma
3. Inflammatory subtypes in asthma
4. Airway inflammation - eosinophils vs. FeNO
5. FeNO levels vs. eosinophilic airway inflammation
6. FeNO levels vs. neutrophilic airway inflammation
7. FeNO and eosinophils
8. FeNO in healthy subjects
9. Factors affecting FeNO
10. Factors affecting FeNO: genetic vs. environmental
11. Cut-points for interpreting FeNO
12. Exhaled NO and asthma diagnosis
13. Exhaled NO in bronchial asthma
14. FeNO in healthy/untreated asthmatic subjects
15. Diagnosing asthma - conventional tests
16. Diagnosing asthma: FeNO and sputum eosinophils
17. Combined FeNO and spirometry
18. FeNO as a diagnostic test
19. Performance characteristics of FeNO
20. FeNO and cough diagnosis (1)
21. FeNO and cough diagnosis (2)
22. FeNO in the assessment of cough
23. Using sputum cell counts for asthma diagnosis
24. Rat challenge - FeNO measurement
25. Laboratory animal allergy (LAA)
26. NO and steroid responsiveness
27. FeNO measurements in anti-inflammatory therapy
28. Sputum eosinophils and ICS in asthma (1)
29. Sputum eosinophils and oral prednisone in COPD
30. Sputum neutrophils and ICS in asthma (2)
31. Hypothesis
32. FEV1 change with fluticasone vs. baseline FeNO
33. PC20AMP improvement with fluticasone (1)
34. PC20AMP improvement with fluticasone (2)
35. Predicting steroid response: EA vs. NEA
36. Steroid responsiveness and non-responsiveness
37. The clinical questions
38. Heterogeneity of treatment response
39. The PACT study
40. The GOAL study
41. FeNO and treatment requirements
42. FeNO and steroid therapy
43. Predicting relapse of asthma after ICS withdrawal
44. Predicting outcome of ICS dose reduction
45. FeNO as a prognostic guide
46. Using FeNO to optimize steroid requirements
47. Sputum cell counts and asthma management
48. NO and inhaled corticosteroid (1)
49. NO and inhaled corticosteroid (2)
50. Cut points and their origin
51. The MAP study
52. The MAP study - FeNO algorithm
53. The MAP study - results (1)
54. The MAP study - results (2)
55. FeNO measurements - using reference values
56. Reference equations for FeNO
57. Predicted versus absolute values (1)
58. Predicted versus absolute values (2)
59. High FeNO despite steroid treatment in children
60. High FeNO - conclusions
61. Using FeNO measurements to monitor asthma
62. Exhaled NO and asthma control
63. FeNO and asthma control (1)
64. Using biomarkers - the timing of signal change
65. Defining a 'clinically meaningful change'
66. FeNO and asthma control (2)
67. Predicting loss of control
68. Biomarker use in complex asthma: discordance
69. Dysfunctional breathing and ICS doses
70. Patient K.P.
71. Patient J.S.
72. Applying FeNO measurements: summary (1)
73. Applying FeNO measurements: summary (2)
74. Conclusions

Topics Covered

• Exhaled nitric oxide (NO) in asthma
• The relationship between exhaled NO and airway inflammation
• Use of exhaled NO in diagnosis of respiratory symptoms
• Exhaled NO as a predictor of steroid responsiveness
• Strengths and weaknesses use of exhaled NO in monitoring asthma
• Guideline for the clinical application of exhaled NO

Links

Series:

• Advances in Asthma

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Taylor, R. (2011, December 29). Advances in asthma: the role of exhaled nitric oxide in the assessment and management of asthma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 3, 2025, from https://doi.org/10.69645/WRUH4110.
Export Citation (RIS)

Publication History

• Published on December 29, 2011

Financial Disclosures

• Prof. Robin Taylor has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.